Member Info for potnak

I bought another £2k worth this week. Can't not do when it's under a pound! Full disclosure though. I will sell them again if we get back to 140 or above in the short term. Easy money. Placings dont bother me, SAR have only ever raised when they needed it and only raised what need. It's why they would need to place, that is the negative big. It would mean no on licence of 737 or licence for 1801 is in the immediate pipeline. AIM is about psychology as well as fundamentals. Placing gives a message to the market that the timescales for deals are longer that most here think. Again, for me, that's fine as my timescales are 2025/26 for the big cash out. Final thought, A HNWi buy in at say a £1 would send us back to £2 or more in an instant.

Yes, great post, Laz. Just got to wait and hope we are in the small percentage of bio minnows that do, eventually come good.

Sfif - if we get through 1b showing some efficacy then there is no reason to think the binary choice will happen until phase 2 data readout. All being well, that's my intended cash out. I've no intention of going past that point. Hopefully, we will be taken out before then.

Why do you say "we are in good hands with our board"? What makes you think that? As far as I can remember, they have missed every deadline they set, every single one. So it can't be that, they have failed to attract institutional investors even though they kept telling us that was the plan. So it can't be that either. So what is it? To me they are akin to the VAL board when all was going well over there. Full of promise but not able to get it over the line. Time will tell if we are in good hands. I believe we have the best board we can afford right now. We shouldn't rock the boat too much but they should definitely know we are here. And yes, no news until September/oct, that will do me. Hopefully we will know if we got through P1a by then.

Parrot that was me scrolling reading posts and not paying attention to the subject line.

Carter, the brow post is from a 2019 RNS but they were saying clinical studies back in a 2018.

Dr Tim Mitchell, CEO of Sareum Holdings plc, said: "The potential for our two preclinical TYK2/JAK1 inhibitors in autoimmune diseases and cancer is gaining increasing clinical validation and we are convinced that SDC-1801 and SDC-1802 represent strong and well-differentiated candidates to address diseases within these areas. We are focused on advancing these exciting preclinical candidates towards human trials as quickly as possible, aiming for first-in-man studies to begin in 2020."

The point I'm making is the were telling us we'd be ready for trials by 2020 but as it turned out, we hadn't even finished preclinical trials by then not even nearly. The pandemic added further delays as fix the MHRA application fiasco. The usual suspects here were talking about buyouts back then too. Thoth was talking about buyouts in 2016! Bless him.

Laz, I'm at the point of no return too. I'm also on a free ride and I have £50k tied up here. It's a lot of money and it's easy to say you are here to the end, win or lose but if it all goes wrong, we will always look back and question if the signs were there all along. I know I have when thinking about the summer of 2021. So I intend to question everything as it happens and make decisions based upon what the board tells us and how they react to the challenges ahead.

It won't come as a surprise to most here but I sit firmly on the fence when it comes to SAR. I use to be super enthusiastic about the potential but years of seemingly not progressing has worn me down. We are years behind where the company said we should be and it isn't all down to the pandemic. The board has to take some responsibility for that and we, as shareholders should be keeping them in check. I happen to agree with the comments about 737. It is a dead duck until we hear otherwise. There is no need to try and convince me of some sort of conspiracy to delay it as if makes no sense, especially when Sierra flew through phase 1/2 trials. We know as a mono, it isn't great. So now the CPF now need to find some deep pockets to take a punt on combo trials. Until then, there is no value.

Getting 1801 to trials has been a saga that has taken 5 or more years since Sareum first stated telling that was the plan. Again, the board need to take some responsibility for that.

There is a danger that the cheerleaders here let the board have an easy ride. The Sareum investors have paid for the research, the salaries and pensions of the board and the ironic thing is a lot of our SAR shares feature in our own retirement planning. The kicker here is if Sareum fail, the board will still get their pensions but the shareholders will get nothing. I'm not particularly worried about how the trials are progressing but when the time comes, we need to start asking some questions to the board. However, I don't think we are quite there yet and IMO, we need to let them get on with the job.

I'm just asking the questions I ask myself. I'm not stating an opinion. The early news releases for the Sierra mentioned 737 as an asset so that suggests it was part of the sale. Why hand it back? Did they just run out of time? Personally, I don't want news of 737 until 1801 is licenced or near licenced. Two bits of big news together will do wonders for the SP. The decision isn't Sareum's as It's CPF's asset but they can sit on it for as long as they want without having to give a reason why. That's good news IMO.

737 honestly, confuses me. On the face of it, it appears that GSK had it on the cheap and chose to give it back! or did they? Had the deadline to progress or hand back already passed or did they know it would pass before the sale of Sierra so the 1.9 billion was purely for Momletinib? I don't buy the idea that they have similar compounds so chose to give it back. They literally could have on licensed or sold it on! and got some of the Sierra spend back straight away. Did they look at the data and think nope, not for us? This would contradict the general consensus of most scientists that have looked at it. So why did it not find a home? Now it is back, what's happening, Tim and especially Parker seemed to indicate that after a short review by CPF and Sareum, they would let us know the next steps and yet we are only 3 months away from it being a year since we were first told it was being handed back to CPF.

I think they know the what next steps are but can't tell us yes and I'm not sure if that is good or bad. I'm hoping that the fact that Sareum hasn't raised yet, and the fact that Tim instantly shut down funding questions with a "no comment" means that funding won't be an issue. 737, IMO is a typical AIM asset. It has no value assigned in the Market Cap of the company but the SP would drop if we got anything less than excellent news for it. I'm always pleased to see the close of the market on a Friday, "no news is good news", as Tim once said.

Yes, I reckon sept at the earliest unless we get news on 737 in the meantime. Though, IMO, they will wait to update on 737 for as long as possible. The last thing the share price needs right now is an RNS stating that ICR are looking for a partner for 737. If would be ok news but it isnt what the market wants to hear. It's a conundrum. If a deal was inbound for 737. Then presumably the upfront would be enough to pay for 1801 phase 2? and that would negate the need for a licence deal until P2 underway.

Just saying, they didn't give a running commentary on how the trials were progressing. No shareholders of course and It would be nice to get news but its too commercially sensitive until data readouts or a licence is announced.

The 737 licence came almost 4 months after the start of the trial. If we are going to licence 1801 early, I'd expect a similar timescale. Its worth noting here, that we didn't hear anything from the trial until the licence news dropped.

Hi Parrot. Don't know why I bothered finding this. It's in the past but I wrote this in Feb.

"I'm not being negative but this isn't all down to backlogs. The 'non approve' came back on time so they looked at and reviewed the application on time. There is more to this than we know and we cant pretend otherwise. The ones who are most confident are also the ones who think negative sentiment means the SP will drop"

I've been investing in AIM for nearly 15 years now and have seen it all. I say it again and again. I'd rather see all views not just one side. I'm not aligned to any side here just stuck in the middle hoping that, one day, we don't get the dreaded "didn't meet primary endpoint RNS" I hold just over 50k shares, I trade small blocks as and when the SP allows but never more than 10% of my holding. I've found the sareum board, mainly Tim M, to be one of the more truthful boards on AIM but they will only tell us what they are required to to tell us.

Jeez, some here. Horse is a very long termer and I think quite a few here read the RNS back in Nov, including me, and I said it at the time. I interpretated the words to mean CTA rejected. It doesn't matter what the reason was.

The problem is, there are some self appointed gate keepers here that label any negative opinion as womblese so lots here don't voice their opinion. It's not FUD but it is a bit disappointing that the so called Womble a have been ones to call the SP movements coirect since the Summer of 2021.

There is no getting away from the fact that Sareum are still an AIM minnow with very little cash runway. Potential investors are rightly nervous about buying im. However, Sareum do have a couple of promising compounds with one currently in a P1 trial with some clear endpoints and data readouts. FWIW, I think the board messed up the MHRA application but didn't "trip over the same rock twice" when applying for trials in Aus. Of course, they won't tell us that so just be pleased that we seem to be rolling along nicely now.

IMO. They picked psoriasis because, it's already an established market with few treatments, it has ready available patients to trial on and if it shows efficacy, the trials will validate the other autoimmune indications.

In an ideal world, There is value in the other indications but SAR would need to fund those trials somehow. Better to on licence and take a cut of future sales (of all indications) which I assume will be built into the royalties. 1801 is essentially a loss leader for 1802. Again, of efficacy is shown and the immune response of 1802 is proven and we may get both licenced at the same time.

Sareum, can only take this so far. We don't have the skills or funds to take this much further than P1 and to be frank, I think the risk to shareholder value is too great to go down that road. Still a long way to go but I think we have started the beginning of the end.

Should have said east/west bidding war.

I still think that Australia was strategically chosen because of easier access to Asian markets. A patent covered in China is of huge value and might be the catalyst for an easy, bidding war for our compounds. Roll on 1b.

Personally, I think we are 2 years away from the point where some LTH will start offloading. P1b next year, wait for data. If good 1801 and 1802 straight into P2.

Both start in 2025. This could be the catalyst for some selling from LTH. Then P2 data readout in 2026 and at that point, I think will have a valuation over a billion, if not 2 billion. Of course all that will need funding. IMO a buyout offer could come anytime after tox and dose studies are done. So many permutations, it's not really worth thinking about. That's why I tell myself 2 years. If it feels like that's a long time. Sareum released several RNS saying P1 trials for 1801 would start in 2019/20. Yet here we are in 2023 with it only just underway. All good and everything still on play and that's all we can hope for until pivotal news.

Think it is, quite a unique situation. Where there are 2 compounds that are essentially the same but have been tweaked enough to be different. I think there are 2 options. We get some sort of deal for 737 that has enough upfront to put 1801 and 1802 through early trials. Or We get a licence for 1801. But where does that leave 1802, will the partner have a first dibs on 1802 clause in the contract or will they secure both compounds from the start? Or will they just take out SAR altogether?

Yes, 1b data is going to be very interesting reading for potential partners. If 1801 inhibition is the same as in mice then if will be game on going into phase 2. Still think 1801 is the loss leader as it were. 1802 potential could bring in the big offers. From a strategic business point of view. An on licence for 1801 would lock us into that partner. So any partners interested in 1802 will be watching the trials closely as it could be cheaper to buy the lot outright.